Successful Treatment of Posttransplant Recurrent Complement C3 Glomerulopathy with Eculizumab


Sahin H., Oguz E. G. , Akoglu H. , Atilgan G., Okyay G. U. , Gursoy G. K. , ...More

IRANIAN JOURNAL OF KIDNEY DISEASES, vol.12, no.5, pp.315-318, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12 Issue: 5
  • Publication Date: 2018
  • Title of Journal : IRANIAN JOURNAL OF KIDNEY DISEASES
  • Page Numbers: pp.315-318

Abstract

Two-thirds of complement C3 glomerulopathy (C3G) recur after transplantation and commonly cause graft loss. There is not a standard treatment protocol for these cases. We present a kidney transplant patient with recurrent C3G who was successfully treated with eculizumab. Nephrotic proteinuria and hernaturia occurred and creatinine levels increased after transplantation. A graft biopsy revealed recurrent C3G. The patient was administered 250 mg pulse methylprednisolone for 3 days and had 9 sessions of plasmapheresis. Since elevated creatinine levels and proteinuria persisted, eculizumab was instituted. A complete remission was observed after 9-month maintenance eculizumab treatment. Eculizumab may be a potentially effective option in kidney transplant patients with recurrent C3G unresponsive to other treatment modalities.